Gilead Sciences saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 67 to 73.
As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.
IBD's unique RS Rating identifies market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
History shows that the stocks that go on to make the biggest gains tend to have an 80 or better RS Rating as they launch their biggest price moves. See if Gilead Sciences can continue to show renewed price strength and hit that benchmark.
Looking For Winning Stocks? Try This Simple Routine
Gilead Sciences stock is building a consolidation with a 74.22 buy point. See if it can break out in volume at least 40% higher than normal, keeping in mind the current market and this being a Friday.
Top and bottom line growth moved higher in the company's most recent quarter. Earnings were up 4%, compared to -68% in the prior report. Revenue increased from -2% to 3%.
The company earns the No. 32 rank among its peers in the Medical-Biomed/Biotech industry group. Regeneron Pharmaceutical and Vertex Pharmaceuticals are also among the group's highest-rated stocks.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
